Objective-Atherosclerosis is a chronic disease characterized by lipid accumulation in the arterial wall. After myocardial infarction (MI), atherosclerotic plaques are infiltrated by inflammatory myeloid cells that aggravate the disease and increase the risk of secondary myocardial ischemia. Splenic myelopoiesis provides a steady flow of myeloid cells to inflamed atherosclerotic lesions after MI. Therefore, targeting myeloid cell production in the spleen could ameliorate increased atherosclerotic plaque inflammation after MI. Approach and Results-Here we show that MI increases splenic myelopoiesis by driving hematopoietic stem and progenitor cells into the cell cycle. In an atherosclerotic mouse model, E-selectin inhibition decreased hematopoietic stem and progenitor cell proliferation in the spleen after MI. This led to reduced extramedullary myelopoiesis and decreased myeloid cell accumulation in atherosclerotic lesions. Finally, we observed stable atherosclerotic plaque features, including smaller plaque size, reduced necrotic core area, and thicker fibrous cap after E-selectin inhibition. Conclusions-Inhibiting E-selectin attenuated inflammation in atherosclerotic plaques, likely by reducing leukocyte recruitment into plaques and by mitigating hematopoietic stem and progenitor cell activation in the spleen of mice with MI.
A therosclerosis is characterized by pathological lipid deposition in the arterial wall, which triggers an inflammatory cascade. 1 During progression of atherosclerosis, monocytes are recruited to lipid-rich plaques. 2 Recruitment is mediated by monocyte attachment to arterial endothelial cells that upregulate adhesion molecules, such as E-selectin, VCAM-1 (vascular cell adhesion molecule 1), and ICAM-1. 3 Leukocyte homing to atherosclerotic plaques occurs in 4 sequential steps: (1) leukocyte tethering and rolling, mediated by selectins; (2) initial leukocyte adhesion to endothelial cells via selectins and PSGL-1 (P-selectin glycoprotein ligand 1); (3) integrin-mediated firm adhesion; and (4) transmigration across the endothelial layer. 4 Selectins mediate leukocyte tethering and rolling, which are the first steps of diapedesis. Once in the plaque, inflammatory monocytes can differentiate into macrophages and produce proteases, such as collagenase, that erode the plaque's fibrous cap. Such erosions leave plaques vulnerable to rupture that results in myocardial infarction (MI).
Recurrent ischemic injuries occur frequently and are often fatal. 5 In ApoE −/− mice, coronary ligation leads to extramedullary myelopoiesis that persists even 12 weeks after the ischemia. 6 Inflammatory myeloid cells produced in the spleen are recruited to atherosclerotic plaques via blood. 7 In ApoE −/− mice, MI increases plaque size, plaque monocyte numbers, and alters monocyte phenotype as monocytes isolated from atherosclerotic lesions after MI express higher levels of inflammatory genes. 6 Subsequent studies, using angiography to measure the progression of nonculprit coronary artery lesions in patients with ST-segment-elevation MI, 8 showed that these patients had faster advancing lesions when compared with a cohort without MI.
Because myeloid cells have high turnover rates in inflammatory tissues, 7,9 they must be replenished by hematopoietic stem and progenitor cells (HSPC). MI diminishes bone marrow levels of hematopoietic stem cell (HSC) retention factors, such as CXCL12 (chemokine C-X-C motif ligand 12) and VCAM-1, triggering HSPC release from the bone marrow. The released HSPC seed the spleen and divide in the presence of stem cell factor to produce myeloid cells that, after being recruited to atherosclerotic plaques, render the lesions more inflamed. 6 This understanding of HSPC's role after MI is supported by clinical data showing higher splenic uptake of the PET (positron emission tomography) tracer 18 F-FDG (fluorodeoxyglucose), which is incorporated by cells with higher energy demands, such as proliferating cells. The spleens and bone marrow of patients with acute MI showed significantly higher PET tracer uptake. 10 Although 18 F-FDG is not specific to a certain cell type, these results may indicate increased cell proliferation in the spleen in patients with acute MI. In a retrospective analysis, patients with higher splenic 18 F-FDG uptake showed increased cardiovascular events after imaging. 11 These studies indicate that splenic activation plays a role in increased atherosclerotic lesion inflammation after MI. However, there is currently no clinically available intervention that can block this process.
HSC proliferation and differentiation are tightly regulated by niche cells, such as endothelial cells, mesenchymal stem cells, among others, in the bone marrow microenvironment. 12 E-selectin, a cell adhesion molecule expressed by sinusoidal bone marrow endothelial cells, regulates HSC fate by promoting progenitor proliferation. 13 HSC proliferation decreased in E-selectin knockout mice and after pharmacological E-selectin inhibition. Whether similar mechanisms are active in the spleen is not well understood. We hypothesized that E-selectin inhibition dampens splenic monocyte production in hypercholesterolemic mice with experimental MI. Previously, we found that MI transiently elevated splenic progenitor proliferation after MI in wild-type mice, 9 and more permanently in ApoE −/− mice after coronary ligation, 6 both resulting in increased extramedullary myelopoiesis. In the current study, we describe that inhibiting E-selectin with a small-molecule glycomimetic antagonist (GMI-1271) significantly decreased HSC proliferation in the spleens of mice with atherosclerosis and MI. Reduced proliferation led to lower HSC and progenitor numbers and attenuated splenic myeloid cell output. Furthermore, after E-selectin inhibition, aortic plaque contained significantly fewer inflammatory myeloid cells. The treatment reduced atherosclerotic plaque size and necrotic core area, whereas plaque fibrous caps were thicker.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

MI Triggers Splenic HSPC Proliferation
To investigate the time course of upstream splenic HSPC proliferation after MI, we ligated the left anterior descending coronary artery. At different time points after MI, we injected wild-type mice with BrdU (bromodeoxyuridine), a thymidine analogue that can be incorporated into DNA strands during the S phase of cell cycle. We found that splenic HSPC proliferation progressively increased after coronary ligation. It peaked on day 3 and returned to steady-state level on day 7 ( Figure 1A-1C ). On day 2 after coronary ligation, HSPC proliferation was >4× higher than in mice without coronary ligation (control, 4.06±0.4 BrdU + HSPC; day 3 after coronary ligation, 17.3±1.9%). Concomitantly, splenic myeloid cell numbers increased at day 4 after myocardial ischemia ( Figure 1D ), thereby indicating that proliferating HSPC differentiated into myeloid cells.
E-Selectin Inhibition Decreases Splenic HSC and Progenitor Proliferation
Splenic HSC and progenitor proliferation fuels extramedullary myelopoiesis. 7, 14 However, the regulation of splenic HSC proliferation (Figure 2A) is not well understood. Because E-selectin expressed by bone marrow sinusoidal endothelial cells promotes HSC proliferation, 13 we hypothesized that inhibiting E-selectin would reduce splenic HSC proliferation. To test this hypothesis, we treated C57BL/6 mice after MI with a small-molecule E-selectin inhibitor (GMI-1271). Surface plasmon resonance revealed that GMI-1271 potently inhibited E-selectin with a K D in the high nanomolar region (0.46 μmol/L). GM-1271's IC50 for E-selectin was 1.75 μmol/L, whereas it was 2.9 mmol/L for L-selectin and >10 mmol/L for P-selectin. These data indicate specificity of GMI-1271 for E-selectin ( Figure I in the online-only Data Supplement). Treatment with GMI-1271 after coronary artery ligation resulted in significantly decreased splenic proliferation of HSC (PBS, 26.4±1.7%; GMI-1271, 17.6±3.2%) and HSPC (PBS, 26.5±1.1%; GMI-1271, 21.3±3.9%; Figure 2B ).
We recently described that MI triggers splenic HSC proliferation, 9 leading to increased inflammatory myeloid cell production that exacerbates atherosclerosis. 6 To investigate the role of E-selectin in splenic HSC proliferation in atherosclerotic mice, we next performed coronary ligation in ApoE −/− mice fed a high-fat diet. After MI, the mice received E-selectin inhibitor injections. GMI-1271 treatment did not alter blood cholesterol levels ( Figure II in the online-only Data Supplement). Cell cycle analysis was done on day 21 after MI ( Figure 2C ). HSPC and HSC were stained for Ki-67, an antigen expressed in cycling cells. DNA marking with PI distinguished cells in S-G2-M phase (ie, proliferating cells) from those in G1 phase ( Figure 2D ). We found that E-selectin inhibition decreased the percentage of HSPC in G1, S-G2-M, and non-G0 phases, whereas the percentage of HSPC in G0 stage was increased ( Figure 2E ). We detected similar effects on splenic HSC proliferation ( Figure 2F ). Interestingly, GMI-1271 treatment did not change bone marrow HSC and HSPC proliferation ( Figure III 
E-Selectin Inhibition Lowers Splenic HSC and Progenitor Numbers
Because inhibiting E-selectin decreased HSC and HSPC proliferation, we investigated whether the treatment also decreased their numbers. For this experiment, we again used ApoE −/− mice fed a high-fat diet. Figure 3A Figure 3B ).
E-Selectin Inhibition Dampens Myelopoiesis
MI-induced activation of splenic HSPC contributes to a systemic rise in myeloid cell numbers, 6 and the spleen supplies myeloid cells in the setting of atherosclerosis. 7, 15 Because E-selectin inhibition significantly reduced HSC and HSPC proliferation in the spleen, we hypothesized that the treatment would also reduce circulating myeloid cell numbers in mice with MI. Indeed, GMI-1271 treatment significantly reduced myeloid cell numbers in the blood (Figure 4A and 4B). Figure 4A shows the gating strategy for monocytes, the inflammatory Ly-6c high monocyte subset, and neutrophils. In Apoe −/− mice, E-selectin inhibition reduced total monocytes, Ly-6c high monocytes, and neutrophil levels by 28%, 41%, and 40%, respectively, as measured 3 weeks after MI ( Figure 4B ). Interestingly, ApoE −/− mice treated with GMI-1271 showed a trend toward increased lymphocyte numbers ( Figure IV in the online-only Data Supplement), which may indicate that E-selectin inhibition influences hematopoietic lineage bias, proliferation of lymphocytes, or lymphocyte migration. 16
Mitigated Inflammation in Atherosclerotic Lesions and Enhanced Stable Plaque Phenotype After E-Selectin Inhibition
Atherosclerosis is associated with systemically increased inflammatory myeloid cells 15, [17] [18] [19] that are recruited to atherosclerotic plaques, a process that partially depends on E-selectin. 4, 20, 21 The presence of inflammatory cells is detrimental to a stable plaque. 22 Because the E-selectin inhibitor effectively curbed myelopoiesis (Figure 4 ), we next investigated whether GMI-1271 treatment might reduce inflammation in atherosclerotic lesions, thus, promoting stable plaques. To test this hypothesis, we induced MI in ApoE −/− mice fed a high-fat diet. ApoE −/− mice were injected with either PBS or GMI-1271 for 3 weeks after coronary ligation. E-selectin inhibition significantly reduced aortic accumulation of myeloid cells, Ly-6c high monocytes, macrophages, and neutrophils ( Figure 5A and 5B ). Diminished lesion inflammation was confirmed by histology, which revealed a smaller CD11bstained area in sections of the aortic root ( Figure 6A and 6B ). Furthermore, plaque size in the aortic root decreased significantly ( Figure 6C ). Matrix metalloproteinases produced by inflammatory myeloid cells erode the fibrous cap, thereby allowing blood to come into contact with thrombogenic materials in the underlying necrotic core. 23 This may result in acute coronary thrombosis and myocardial ischemia. Accordingly, E-selectin inhibitor treatment might promote stable plaque features, such as small necrotic cores and thick fibrous caps. To test this hypothesis, we performed Masson staining of aortic root sections from ApoE −/− mice 3 weeks after MI. We found that GMI-1271 treatment significantly reduced necrotic core area and increased fibrous cap thickness ( Figure 6D and 6E) . We also investigated the impact of E-selectin inhibition on myocardial healing after infarction by inducing MI in C57BL/6 wild-type mice. Cardiac magnetic resonance imaging was used to quantify infarct size on day 1 and measure heart failure on day 21 after MI ( Figure VA -VD in the online-only Data Supplement). Initial infarct size was determined on day 1 after coronary artery ligation by delayed gadolinium enhancement and was similar for both groups ( Figure VC 
Discussion
The adhesion molecule E-selectin is known for its role in recruiting inflammatory leukocytes into the arterial wall. In the setting of atherosclerosis, E-selectin is expressed by activated endothelial cells and binds carbohydrate ligands on leukocytes, leading to cell adhesion to the endothelial surface. Interleukin-1 and tumor necrosis factor-α are known instigators of E-selectin expression by endothelial cells. 24 The adhesion molecule promotes a critical step in monocyte recruitment and, thus, contributes to plaque inflammation. 4 Recently, it was shown that E-selectin also promotes HSC activity in the bone marrow and that its inhibition can reduce hematopoietic progenitor activity in this organ. 13 Here we describe that E-selectin also regulates splenic myelopoiesis in mice with atherosclerosis and MI.
The spleen serves as a source of monocytes in ischemic heart disease. 25 Hyperlipidemia 7 and myocardial injury 9 lead to hematopoietic progenitor retention in this organ, which consequently supplies myeloid cells to the growing atherosclerotic plaque and to ischemic myocardium. Although first clinical data indicate splenic activation in patients with acute coronary syndrome, 11 the regulation of splenic hematopoiesis is incompletely understood. Given previous reports on E-selectin upregulation after MI 26 and its association with hyperlipidemia and cardiovascular disease in general, 27 we studied the effects of the E-selectin inhibitor GMI-1271, which has a good safety profile in humans, 28 in mice with MI and preexisting atherosclerosis. Previous work established that in this scenario, which mimics the occurrence of myocardial ischemia in patients with atherosclerosis, the spleen provides an overabundance of inflammatory monocytes to atherosclerotic plaques throughout the arterial system, possibly promoting reinfarction. 6 Our data imply that GMI-1271 efficiently dampens inflammation in mice with atherosclerosis and MI, partially through reducing splenic production of myeloid cells.
Given that E-selectin has several other biological roles, the observed GMI-1271 effects are likely a consequence of several mechanisms, which may include inhibition of monocyte adhesion to endothelial cells. GMI-1271 also inhibits procoagulatory leukocyte action. 29 These 2 mechanisms, among others that are yet unknown, may have contributed to the observed reduction in plaque size and may be beneficial in the clinical setting.
Monocytes and macrophages are essential for efficient infarct healing. In wild-type mice with reduced leukocytes, for instance because of splenectomy or macrophage depletion, rupture rates are increased and post-MI remodeling leads to heart failure. 30, 31 In patients, this scenario is rare because most of them have blood monocytosis and likely an overabundance of infarct macrophages. If there are too many inflammatory monocytes and macrophages residing in the infarct, resolution of inflammation is impaired, which also impedes infarct healing. 32 Thus, it has been postulated that there is an optimal range of monocyte supply to acute infarcts. 30 We therefore tested in wild-type mice whether GMI-1271 influences infarct healing. E-selectin inhibition reduced myeloid cell recruitment, but did not change scar size or left ventricular remodeling. These data indicate that GMI-1271 may have a favorable safety profile in patients with acute MI. Future experiments that focus on infarct healing in a setting of systemic monocyte/macrophage overabundance, for instance in mice with preexisting atherosclerosis, 32 will show whether anti-inflammatory properties of GMI-1271 support post-MI recovery of the left ventricle.
We did not observe an effect of GMI-1271 on bone marrow hematopoiesis in mice with atherosclerosis and MI. In steady state or after myelotoxic treatment, genetic deletion or E-selectin inhibition promotes HSC quiescence and survival. 13 We speculate that the bone marrow's state in mice with atherosclerosis and after MI may be altered and that these changes may interfere with drug distribution. An alternative explanation is that MI triggers strong and multifactorial hematopoiesis activation pathways, including via sympathetic nervous signaling 6 and circulating interleukin-1b, 33 which may override effects of E-selectin inhibition.
Our study has several limitations. We began to investigate splenic GMI-1271 effects in a worst-case scenario, a combination of acute (MI) and chronic (atherosclerosis) inflammation. Arguably, the clinical need for decisive but specific anti-inflammatory interventions is highest in this setting. Nevertheless, it is of interest whether similar drug action is observed in ApoE −/− mice without MI. Further, given the multiple biological functions of E-selectin, our data do not provide insight to what degree GMI-1271's splenic actions contributed to the observed phenotype. Thus, future studies should decipher the precise quantitative contribution of GMI-1271 inhibition of splenic cell production versus leukocyte migration. Finally, future studies should focus on the precise E-selectin ligand(s) in the spleen and reveal the identity of splenic cells involved in E-selectin-mediated information transfer. 
